Medications for Nightmares
Prazosin is the first-line medication for treating nightmares, particularly those associated with PTSD, with a Level A recommendation from the American Academy of Sleep Medicine. 1, 2
Prazosin: First-Line Pharmacotherapy
Prazosin should be initiated at 1 mg at bedtime and titrated upward by 1-2 mg every few days based on nightmare response and tolerability. 1, 2
Dosing Strategy
- Start: 1 mg at bedtime 1, 2
- Titration: Increase by 1-2 mg every few days 1, 2
- Average effective dose: Approximately 3 mg nightly 1, 2
- Therapeutic range: 1 mg to >10 mg per night 1, 2
- Higher doses for severe PTSD: Veterans with severe combat-related nightmares have successfully used 9.5-13.3 mg daily, with some case reports documenting efficacy up to 45 mg daily 3, 1, 2, 4
Evidence Base
- Three Level 1 placebo-controlled trials (n=98) demonstrated statistically significant reductions in trauma-related nightmares, with CAPS nightmare scores decreasing from baseline 4.8-6.9 to 3.2-3.6 after prazosin treatment over 3-9 weeks. 1, 2
- The mechanism involves reducing CNS adrenergic activity, as elevated norepinephrine levels in PTSD contribute to nightmare generation and sleep disruption 1
Critical Monitoring Requirement
Monitor for orthostatic hypotension by checking sitting and standing blood pressure before the first dose and after each titration step. 1, 2 This is the primary safety concern, though prazosin was generally well-tolerated across all clinical trials with only mild, transient dizziness reported in some subjects 3, 1
Important Contradictory Evidence
A large 2018 VA randomized trial (n=304) found no significant difference between prazosin and placebo at 10- and 26-week follow-up, though 78% of participants were concurrently receiving antidepressants, which may have confounded results. 2 Despite this negative trial, the preponderance of earlier evidence and clinical experience supports prazosin's efficacy, particularly when used as monotherapy or with careful attention to adequate dosing.
Second-Line and Alternative Pharmacologic Options
When Prazosin Fails or Is Contraindicated
Clonidine (0.2-0.6 mg in divided doses) may be considered as a second-line agent, though evidence is limited to Level 4 case series showing efficacy in 11 of 13 refugees. 1, 2 Despite over 20 years of clinical use in severely traumatized refugees, no randomized controlled trials have been conducted 1
Topiramate can be added as adjunctive therapy, starting at 12.5-25 mg daily and increasing by 25-50 mg every 3-4 days, with 91% of responders achieving benefit at ≤100 mg/day. 2
Atypical antipsychotics warrant consideration based on real-world effectiveness data: 1, 2, 5
- Risperidone (1.0-6.0 mg): 77% success rate in 81 trials 5
- Olanzapine (2.5-10.0 mg): 100% success (full remission) in 5 separate patients 5
- Quetiapine (12.5-800.0 mg): 50% success rate in 72 trials 5
Trazodone (mean dose 212 mg, range 25-600 mg) reduced nightmare frequency from 3.3 to 1.3 nights per week in 72% of 60 veterans, but 60% experienced side effects (daytime sedation, dizziness, headache, priapism, orthostatic hypotension) and 19% discontinued due to adverse effects. 1
Other Options with Limited Evidence (Level C)
- Mirtazapine (7.5-30.0 mg): 50% success rate 5
- Terazosin (50.0-300.0 mg): 64% success rate 5
- Cyproheptadine (4-12 mg at bedtime): Variable response from complete remission to decreased intensity/frequency 6
- Low-dose cortisol (10 mg/day): Reduced nightmare frequency in 2 of 3 civilians with PTSD 1
Medications NOT Recommended
The following medications should be avoided for nightmare treatment: 2
- Clonazepam: Not recommended per 2018 AASM position paper 2
- Venlafaxine: Not recommended per 2018 AASM position paper 2
- Benzodiazepines: Contraindicated for PTSD per 2024 VA/DoD guidelines due to limited efficacy and poorer quality-of-life outcomes 2
- Cannabis and cannabis-derived products: Not recommended per 2024 VA/DoD guidelines 2
- Nefazodone: Not recommended as first-line due to hepatotoxicity risk 1
Non-Pharmacologic First-Line Therapy
Image rehearsal therapy (a form of cognitive behavioral therapy for nightmares) is recommended as first-line treatment for both PTSD-associated nightmares and nightmare disorder, and should be considered before or alongside pharmacotherapy. 2, 7 This is a critical point often overlooked—behavioral interventions have strong evidence and should not be relegated to second-line status.
Clinical Algorithm
Screen for PTSD-related versus idiopathic nightmares and assess for contraindications (severe hypotension, renal failure, pregnancy) 2
Initiate prazosin 1 mg at bedtime with baseline orthostatic blood pressure monitoring 1, 2
Titrate by 1-2 mg every few days to effective dose (typically ~3 mg, range 1-10+ mg; higher doses up to 15-16 mg may be needed in severe PTSD) 3, 1, 2
Re-evaluate after 3-9 weeks: If response is inadequate, consider increasing to higher doses (up to 15-16 mg or even higher in refractory cases) or adding topiramate 3, 2, 4
If prazosin fails or is not tolerated, switch to clonidine, atypical antipsychotics (particularly risperidone or olanzapine based on real-world data), or other alternatives 2, 5
Incorporate concurrent image rehearsal therapy or trauma-focused psychotherapy as a core component of treatment 2, 7
Common Pitfalls to Avoid
- Underdosing prazosin: Many clinicians stop at 3-5 mg when patients with severe PTSD may require 10-16 mg or higher for adequate response 3, 2, 4
- Failing to monitor blood pressure: Orthostatic hypotension is the primary safety concern and must be checked systematically 1, 2
- Ignoring behavioral interventions: Image rehearsal therapy has strong evidence and should be offered concurrently, not as an afterthought 2, 7
- Using benzodiazepines: These are contraindicated in PTSD and worsen quality of life 2
- Discontinuing prazosin abruptly: Veterans frequently returned to baseline nightmare intensity when prazosin was stopped, suggesting need for gradual taper and long-term maintenance 3